everything-possible-shutterstock-com-2
everything possible / Shutterstock.com
14 April 2016Americas

Regeneron agrees CRISPR/Cas licensing deal

Regeneron Pharmaceuticals has agreed a licensing deal that it says will enable it to advance CRISPR/Cas gene-editing technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
29 October 2015   Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.
Americas
11 March 2016   The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

More on this story

Americas
29 October 2015   Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.
Americas
11 March 2016   The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

More on this story

Americas
29 October 2015   Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.
Americas
11 March 2016   The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.